3Q US Biotech VC Investment Balancing Atop Industry's Peak
This article was originally published in Scrip
Executive Summary
The $2.06bn in venture capital that private US biotechnology firms raised during the third quarter almost matched the industry's near record-breaking second quarter total, keeping 2015 VC investment on track to beat 2014 despite a downturn in public biotech valuations that began in the third quarter.